Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Consensus Price Target from Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $3.33.

A number of research firms recently weighed in on SYRS. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com assumed coverage on Syros Pharmaceuticals in a report on Tuesday, December 31st. They issued a “sell” rating on the stock. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th.

Insider Transactions at Syros Pharmaceuticals

In related news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Exome Asset Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares in the last quarter. Certuity LLC acquired a new position in Syros Pharmaceuticals during the second quarter worth $109,000. Acadian Asset Management LLC lifted its stake in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after buying an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Price Performance

Syros Pharmaceuticals stock opened at $0.24 on Thursday. The stock has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $2.53. Syros Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $7.98. The company has a market capitalization of $6.52 million, a PE ratio of -0.08 and a beta of 1.31. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the business posted ($1.35) earnings per share. Analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.